GWM
CTKB icon

Gilpin Wealth Management’s Cytek Biosciences CTKB Stock Holding History

Gilpin Wealth Management’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$40 Sell
9
-4
-31% -$17 ﹤0.01% 1054
2026
Q1 		$57 Buy
13
+4
+44% +$19 ﹤0.01% 981
2025
Q4 		$46 Buy
+9
New +$42 ﹤0.01% 956

Other funds holding CTKB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $386M AUM 2.37% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Gilpin Wealth Management's CTKB Position: Q2 2026 in Review

Gilpin Wealth Management reduced its Cytek Biosciences (CTKB) stake by 31% in Q2 2026, selling an estimated $17 and leaving 9 shares worth $40. The position accounts for ﹤0.01% of the portfolio, ranked #1054.

Gilpin Wealth Management first reported a position in CTKB in Q4 2025 and has held it in 3 quarters since. The position peaked at $57 in Q1 2026. 155 funds tracked by Wall St. Rank hold CTKB as of Q2 2026.

  • Gilpin Wealth Management held 9 shares of Cytek Biosciences worth $40 as of Q2 2026.
  • Gilpin Wealth Management sold 4 Cytek Biosciences shares in Q2 2026, an estimated $17.
  • Cytek Biosciences made up ﹤0.01% of Gilpin Wealth Management's portfolio in Q2 2026, its #1054 holding.
  • Gilpin Wealth Management first reported a position in Cytek Biosciences in Q4 2025 and has held it in 3 quarters since.
  • Gilpin Wealth Management's Cytek Biosciences position peaked at $57 in Q1 2026.
  • 155 funds tracked by Wall St. Rank held Cytek Biosciences as of Q2 2026.

Based on Gilpin Wealth Management's 13F filing for Q2 2026, filed 24 Jul 2026.